Assess Terlipressin for Hepatorenal Syndrome
December 2022
Terlipressin (Terlivaz) will be the first FDA-approved med for hepatorenal syndrome with acute kidney injury (HRS-AKI).
HRS-AKI typically occurs in patients with cirrhosis and ascites who develop splanchnic vasodilation. This causes decreased perfusion to the kidneys.
The best treatment is a liver transplant...but many patients don’t qualify for or live long enough to get a transplant.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote